May 20, 2022

905 On the Bay

For Tech Lovers

111, Inc. Enters into Initial-At any time Strategic Partnership with BeiGene

7 min read

SHANGHAI, March 17, 2021 /PRNewswire/ — 111, Inc. (“111” or the “Business”) (Nasdaq: YI), a foremost tech-enabled healthcare platform enterprise dedicated to digitally connecting patients with drugs and health care solutions in China, announced nowadays it has entered into a strategic cooperation settlement with BeiGene, Ltd. (NASDAQ:BGNE HKEX:06160), a business-stage biotechnology enterprise concentrated on establishing and commercializing revolutionary medicines all over the world.

BeiGene at present markets two internally uncovered oncology medications in China: BTK inhibitor, BRUKINSA® (zanubrutinib), and anti-PD-1 antibody, tislelizumab. It also marketplaces or plans to industry in China extra oncology solutions certified from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) firm, and EUSA Pharma.

Cancer is the primary induce of dying in China, and the quantity of cancer patients is on the rise. In accordance to data from the Intercontinental Company for Investigate on Cancer (IARC) of the Planet Wellness Firm (WHO), in 2020, 4.6 million new scenarios of cancers had been identified in China, accounting for 23.7{888a2f61c345d2e855d0f46d172f155075abed3efdb13b6aef551f16df00e7f6} of the world’s overall scenarios, and there were being 3 million cancer fatalities in the region, accounting for 30{888a2f61c345d2e855d0f46d172f155075abed3efdb13b6aef551f16df00e7f6} of the world’s overall. In the meantime, most cancers cure methods are primarily concentrated in China’s 1st- and 2nd-tier cities. Hence, the latest obstacle in the treatment of cancer in China lies not only in the availability of safe and sound and efficacious medicine, but also in the truth that a huge number of most cancers individuals in the region deal with the unfortunate circumstance of needing to search for both rapid healthcare treatment and extensive-time period observe-up treatment exterior of their regional communities.

Answering the urgent contact to make cancer care additional economical and client-friendly in China, the two corporations will cooperate around a “Online + Medicine & Health care” design, leveraging 111’s World wide web clinic, intelligent provide chain community, info-pushed AI alternatives, these kinds of as digital advertising, and on line and offline direct-to-client (DTP) delivery of medications to develop an one of a kind oncology management system. The platform will further more empower medical doctors to strengthen the performance of affected person administration, particularly for sufferers outdoors of the medical center, and will not only lengthen their company cycles, but also develop their service radius. At the exact same time, as a result of this productive and effortless physician-patient conversation platform, it will be probable to offer patients with a electronic, one-prevent support for healthcare treatment and drugs, bettering the accessibility of BeiGene’s impressive oncology drugs.

According to Dr. Wu Xiaobin, president of BeiGene, the Online+ product will be a catalyst for driving innovation in oncology, and he hopes that this partnership with 111 will empower BeiGene to even more its innovative plans as a result of the wings of digitization. By leveraging the energy of the Net, BeiGene will be ready to deliver its impressive drugs and services to far more clients nationwide.

Ms. Wu Qingyi, Main Business Officer of BeiGene Higher China, explained, “In buy to further more endorse the commercialization of oncology revolutionary medicines, we hope to use 111’s marketplace major technological know-how and electronic company to establish the “past mile” shipping of oncology disorder healthcare services in China. This will make it possible for us to offer additional high-good quality progressive medicines and increase the accessibility of our health-related resources to individuals in China.”

Dr. Yu Gang, Co-founder and Government Chairman of 111, Inc., commented, “We are psyched to associate with a primary firm specializing in the advancement of innovative therapies in oncology. Both of those within and outside of China, common pharmaceutical product promoting primarily targets clinicians, with reasonably little awareness devoted to conclude sufferers. However, in the period of digital health care services, and by way of the empowerment of the World-wide-web, pharmaceutical providers can now provide “patient-centered” treatment by prioritizing the requires of the people. With the Internet’s capacity to transcend the boundaries of time and geography, it can support health professionals create genuinely integrated on-line and offline disease administration expert services all through the affected individual treatment continuum – from diagnosis to procedure to put up treatment method follow-up treatment. We are assured that, by relying on our thorough electronic “medical treatment + medicine” system, 111 can support broaden the commercial arrive at of BeiGene’s innovative oncology medicines as perfectly as progress the adaption of revolutionary clinical company types in China.”

111’s strategically positioned, know-how-pushed achievement facilities at the moment serve far more than 300,000 pharmacies in China that comprise its on-line and offline built-in digital pharmacy network, empowering the Firm’s means to give 24-hour shipping and delivery in most key towns and 72-hour supply nationwide.

About BeiGene

BeiGene is a world, industrial-phase biotechnology corporation targeted on identifying, creating, manufacturing, and commercializing ground breaking medications to enhance procedure results and obtain for patients throughout the world. Our 5,400+ personnel close to the environment are fully commited to expediting the development of a varied pipeline of novel therapeutics. We at the moment market place two internally identified oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also sector or plan to current market extra oncology products and solutions in China licensed from Amgen Inc. Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) corporation and EUSA Pharma and have entered a collaboration with Novartis Pharma AG for Novartis to establish and commercialize tislelizumab in North The united states, Europe and Japan. To learn far more about BeiGene, make sure you check out and abide by us on Twitter at @BeiGeneUSA.

About 111, Inc.

111, Inc. (NASDAQ: YI) (“111” or the “Enterprise”) is a main tech-enabled healthcare platform enterprise fully commited to digitally connecting sufferers with medication and healthcare services in China. The Business offers people with greater access to pharmaceutical merchandise and health care products and services specifically by its on the net retail pharmacy, 1 Pharmacy, and indirectly by means of its offline digital pharmacy community. The Organization also offers on the net healthcare services by way of its internet clinic, 1 Clinic, which offers shoppers with expense-productive and effortless on the web session, digital prescription provider, and affected person management services. In addition, the Company’s on the web wholesale pharmacy, 1 Medication Market, serves as a a single-halt store for pharmacies to supply a extensive variety of pharmaceutical merchandise. With the biggest virtual pharmacy community in China, 111 enables offline pharmacies to better provide their consumers with cloud-based services. 111 also presents an omni-channel drug commercialization platform to its strategic partners, which involves services these as digital advertising, client instruction, data analytics, and pricing monitoring.

For a lot more facts on 111, you should take a look at:

Ahead-On the lookout Statements

This press release is made up of forward-searching statements. These statements represent “ahead-looking” statements in just the meaning of Portion 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These ahead-looking statements can be identified by terminology this sort of as “will,” “expects,” “anticipates,” “future,” “intends,” “designs,” “believes,” “estimates,” “target,” “self-assured” and identical statements. Amongst other things, the Enterprise Outlook and quotations from management in this announcement, as effectively as 111’s strategic and operational plans, have ahead-searching statements. 111 may possibly also make created or oral forward-wanting statements in its periodic stories to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in push releases and other published materials and in oral statements produced by its officers, administrators or staff to third functions. This sort of statements are primarily based upon management’s recent anticipations and present-day industry and functioning circumstances and relate to occasions that contain recognized or unfamiliar challenges, uncertainties and other factors, all of which are difficult to predict and several of which are beyond the Firm’s management. Ahead-on the lookout statements contain inherent pitfalls, uncertainties and other things that could bring about precise benefits to vary materially from those contained in any these statements. Opportunity dangers and uncertainties include things like, but are not confined to, uncertainties as to the Company’s means comply with extensive and evolving regulatory needs, its means to compete successfully in the evolving PRC typical well being and wellness market place, its means to manage the development of its business and enlargement ideas, its capability to attain or preserve profitability in the upcoming, its means to command the risks associated with its pharmaceutical retail and wholesale firms, and the Company’s potential to satisfy the standards needed to preserve listing of its ADSs on the Nasdaq World wide Industry, such as its potential to treatment any non-compliance with Nasdaq’s continued listing criteria. Additional facts pertaining to these and other dangers, uncertainties or variables is incorporated in the Company’s filings with the U.S. Securities and Trade Commission. All info presented in this push release is as of the day of this press launch, and 111 does not undertake any obligation to update any ahead-on the lookout assertion as a final result of new info, potential gatherings or otherwise, besides as expected below applicable legislation.

Supply 111, Inc.

Related Inbound links © All rights reserved. | Newsphere by AF themes.